---
title: "IMRX.US (IMRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IMRX.US/news.md"
symbol: "IMRX.US"
name: "IMRX.US"
parent: "https://longbridge.com/en/quote/IMRX.US.md"
datetime: "2026-05-21T02:03:58.210Z"
locales:
  - [en](https://longbridge.com/en/quote/IMRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IMRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IMRX.US/news.md)
---

# IMRX.US (IMRX.US) — Related News

### [Immuneering (IMRX) Gets a Buy from Chardan Capital](https://longbridge.com/en/news/286964427.md)
*2026-05-19T20:35:52.000Z*
> Chardan Capital analyst Geulah Livshits has reiterated a Buy rating on Immuneering (IMRX) with a price target of $20.00.

### [Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary](https://longbridge.com/en/news/286561646.md)
*2026-05-15T12:01:01.000Z*
> Immuneering Corp reported Q1 2026 results with revenue of $13.78M and a net income of $13.46M, showing improvements from

### [Immuneering | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286558957.md)
*2026-05-15T11:45:19.000Z*
### [Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates | IMRX Stock News](https://longbridge.com/en/news/286557558.md)
*2026-05-15T03:35:26.000Z*
> Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates | IMRX Stock News

### [Immuneering To Present New Phase 2a Data For Atebimetinib In Treating Pancreatic Cancer On June 1](https://longbridge.com/en/news/283630575.md)
*2026-04-22T09:10:48.000Z*
> Immuneering Corporation (IMRX) will present updated Phase 2a trial data for Atebimetinib in treating pancreatic cancer a

### [Immuneering Presents Encouraging CtDNA Data For Atebimetinib In Treating Cancer](https://longbridge.com/en/news/283456896.md)
*2026-04-21T07:45:32.000Z*
> Immuneering Corporation (IMRX) presented promising ctDNA data for its cancer drug Atebimetinib at the AACR annual meetin

### [3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026](https://longbridge.com/en/news/283044281.md)
*2026-04-16T19:06:50.000Z*
> Analysts recommend three high-risk, high-reward stocks: Kura Oncology (KURA), Angel Studios (ANGX), and Immuneering (IMR